Targacept Halts TC-5214 Overactive Bladder Program

(RTTNews) - Targacept, Inc. (TRGT) on Monday announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder.

In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency and an improvement that did not reach statistical significance on episodes of urinary incontinence per 24 hours, after 12 weeks of treatment.

As a consequence of the results, Targacept said it is discontinuing further development of TC-5214 in overactive bladder.

"Although TC-5214 provided dose-dependent efficacy on several endpoints during the course of treatment, the results were not compelling enough to justify the compound's continued development in overactive bladder," said Dr. Stephen A. Hill, Targacept's President and Chief Executive Officer.